The company explained that the U.S. Food and Drug Administration (FDA) removed its clinical hold on the studies, and will allow it "to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.